Calculate the Eczema Area and Severity Index (EASI) for atopic dermatitis using the standard 4-region weighted scoring method.
The Eczema Area and Severity Index (EASI) is a validated outcome measure for assessing atopic dermatitis severity. It evaluates four clinical signs — erythema, edema or papulation, excoriation, and lichenification — across four body regions weighted by body surface area proportion.
EASI scores range from 0 to 72, with commonly used severity bands from clear to very severe. Response endpoints such as EASI-50 or EASI-75 require comparison with a documented baseline score rather than simple interpretation of a single visit in isolation.
This calculator is designed for structured EASI scoring in clinical practice, treatment monitoring, and research documentation. The regional breakdown helps show which body areas are driving the current score.
Atopic dermatitis often changes gradually over time, so structured measurement is more useful than a vague description like “better” or “worse.” EASI gives a reproducible way to document current severity and compare visits more consistently.
It is especially useful when treatment decisions, follow-up notes, or research-style documentation need an objective severity framework.
EASI = 0.1 × (Head signs sum × area) + 0.3 × (Trunk signs sum × area) + 0.2 × (Upper limb signs sum × area) + 0.4 × (Lower limb signs sum × area) Signs sum = Erythema + Edema/Papulation + Excoriation + Lichenification Each sign is scored 0-3 Area is scored 0-6 Range: 0-72
Result: EASI 12.0 — Moderate
With moderate area involvement and mild-to-moderate sign intensity across multiple regions, the weighted total is 12.0, which falls in the moderate range. That score describes current severity; treatment response still requires comparison with a baseline visit.
EASI is excellent for describing how severe the dermatitis looks at a given visit. It is also useful for response tracking, but only when the current score is compared against a true baseline.
Each body region contributes differently because the weighting is based on the approximate proportion of body surface area represented by that region. That is why identical sign intensity can affect the total score differently depending on location.
For routine care, the main value is consistency. If the same team uses the same approach over time, EASI becomes a strong way to show whether the patient is meaningfully improving, stable, or flaring.
Last updated:
This calculator applies the canonical EASI framework by scoring area involvement from 0 to 6 in each of the four body regions and the four clinical signs from 0 to 3 per region, then multiplying each regional subtotal by the standard body-region weight before summing the total 0-to-72 score. The goal is structured severity documentation for atopic dermatitis using the same framework commonly used in trials and dermatology follow-up.
The page treats EASI as a current-severity measure. Response endpoints such as EASI-50, EASI-75, and EASI-90 require comparison with a documented baseline score, so they should not be inferred from the current score alone without a baseline value.
EASI-50 means the current EASI score is 50% lower than a documented baseline score. It is a response endpoint, not a number you can infer from a single visit by halving the current score. EASI-75 and EASI-90 work the same way.
That depends on the care setting. It is often repeated during treatment changes, clinical follow-up, or trial visits so the direction and magnitude of change can be documented consistently.
It is reasonably reliable when assessors are trained and use the score consistently, but any clinical scoring system is still improved by shared definitions and experience.
EASI focuses on physician-assessed signs and area. SCORAD includes more patient-symptom content such as itch and sleep loss, so the two tools answer related but not identical questions.
EASI can help describe disease burden and track response, but actual biologic decisions depend on the full picture: treatment history, symptom burden, body area involved, guideline criteria, and payer rules.
Yes, EASI is widely used in children as well as adults. The same basic scoring framework applies, although treatment decisions and interpretation still depend on age and clinical context.